Bulk Pharmaceutical API Sources for MINITRAN

Bulk Pharmaceutical API Sources for MINITRAN

Vendor	Vendor Homepage	Vendor Sku	API Url
Clearsynth		CS-O-01966
Sigma-Aldrich		T-002_CERILLIAN
Sigma-Aldrich		T-021_CERILLIAN
Sigma-Aldrich		T-022_CERILLIAN
AKos Consulting & Solutions		AKOS030254238
LGC Standards		DRE-XA15586000AL

MINITRAN Bulk Active Pharmaceutical Ingredient (API) Sources

Last updated: February 19, 2026

This analysis identifies key suppliers of Minoxidil, the bulk active pharmaceutical ingredient (API) for MINITRAN, a topical treatment for androgenetic alopecia. The report details manufacturing capabilities, regulatory compliance, and geographic distribution of primary API producers, providing critical data for supply chain and R&D professionals.

What is MINITRAN?

MINITRAN is a brand name for a topical formulation containing Minoxidil as the active pharmaceutical ingredient. Minoxidil is a potassium channel opener that promotes vasodilation, and its application to the scalp is known to stimulate hair follicle growth [1]. It is primarily used to treat androgenetic alopecia (male-pattern baldness and female-pattern hair loss).

What is the Active Pharmaceutical Ingredient (API) for MINITRAN?

The active pharmaceutical ingredient (API) for MINITRAN is Minoxidil. Its chemical name is 2,4-diamino-6-piperidinopyrimidine 3-oxide, and its CAS number is 38304-91-5 [2]. Minoxidil is a crystalline solid, typically white to off-white in color.

Who are the Primary Bulk API Manufacturers of Minoxidil?

The global supply of Minoxidil API is concentrated among a limited number of manufacturers, primarily located in China and India. These manufacturers supply the bulk API to pharmaceutical companies that formulate the finished dosage form, such as MINITRAN.

Key Minoxidil API Manufacturers:

• Anqiu Lexiang Pharmaceutical Co., Ltd. (China)

  • Capacity: Reports indicate significant production capacity, though specific figures are proprietary.
  • Regulatory Status: Holds various international certifications and has undergone inspections by regulatory bodies in major markets.
  • Product Focus: Specializes in APIs for dermatological and cardiovascular applications.

• Hebei Veyong Pharmaceutical Co., Ltd. (China)

  • Capacity: A major producer with large-scale manufacturing facilities.
  • Regulatory Status: Operates under Good Manufacturing Practices (GMP) and is a supplier to regulated markets.
  • Product Focus: Extensive portfolio of APIs, including Minoxidil.

• Xi'an Tiankai Biotechnology Co., Ltd. (China)

  • Capacity: A growing manufacturer with increasing global market share for select APIs.
  • Regulatory Status: Pursues compliance with international pharmacopeial standards.
  • Product Focus: Offers a range of pharmaceutical intermediates and APIs.

• Aarti Industries Limited (India)

  • Capacity: One of the largest Indian manufacturers of specialty chemicals and pharmaceuticals, with substantial API production.
  • Regulatory Status: Possesses US FDA, EDQM, and other international regulatory approvals.
  • Product Focus: Broad API portfolio, including Minoxidil, used in global pharmaceutical markets.

• Sarthak Remedies Pvt. Ltd. (India)

  • Capacity: A prominent Indian API producer with established manufacturing infrastructure.
  • Regulatory Status: Complies with GMP guidelines and supplies to various international markets.
  • Product Focus: Manufactures a range of APIs, with Minoxidil being a key product.

• Shandong Xinhua Pharmaceutical Co., Ltd. (China)

  • Capacity: A large, established pharmaceutical enterprise with diverse API manufacturing capabilities.
  • Regulatory Status: Holds numerous international certifications and has a long history of supplying global markets.
  • Product Focus: Produces a wide array of APIs, including those for hair loss treatments.

What are the Regulatory Requirements for Minoxidil API?

Manufacturers of Minoxidil API must adhere to stringent regulatory requirements to ensure product quality, safety, and efficacy. These include:

• Good Manufacturing Practices (GMP): Compliance with GMP regulations, as set forth by agencies like the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and China National Medical Products Administration (NMPA), is mandatory. This covers all aspects of production, from raw material sourcing to finished API release [3].
• Pharmacopeial Standards: Minoxidil API must meet the specifications outlined in major pharmacopeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These standards define purity, impurity profiles, physical characteristics, and analytical testing methods [4].
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory authorities. These confidential documents contain detailed information about the manufacturing process, facilities, and quality control of the API. Pharmaceutical companies reference these DMFs when seeking approval for their finished drug products.
• Impurity Profiling: Stringent control and characterization of impurities are critical. Regulatory bodies require manufacturers to identify, quantify, and control process-related impurities and degradation products within defined limits.
• Stability Testing: Comprehensive stability studies are required to determine the shelf-life of the API under various storage conditions.

What is the Typical Manufacturing Process for Minoxidil API?

The synthesis of Minoxidil typically involves a multi-step chemical process. While specific proprietary routes vary between manufacturers, a common pathway includes [5]:

1. Condensation: Reaction of guanidine or a related precursor with a reactive pyrimidine derivative.
2. Oxidation: Introduction of the N-oxide group, a critical step in forming the active molecule. This is often achieved using oxidizing agents like hydrogen peroxide or peracids.
3. Amine Substitution: Introduction of the piperidino group through reaction with piperidine.
4. Purification: Multiple crystallization and filtration steps are employed to achieve the required purity. This often involves recrystallization from suitable solvents (e.g., ethanol, water).
5. Drying and Milling: The purified API is dried to remove residual solvents and then milled to achieve the desired particle size distribution for formulation.

Key Considerations in Manufacturing:

• Raw Material Sourcing: Reliable sourcing of high-quality starting materials is crucial for consistent API production.
• Process Control: Strict control over reaction parameters (temperature, pressure, pH, reaction time) is essential to maximize yield and minimize impurity formation.
• Solvent Selection: The choice of solvents for reaction and crystallization impacts purity, yield, and environmental considerations.
• Waste Management: Chemical synthesis generates byproducts and waste streams that require proper handling and disposal in compliance with environmental regulations.

What are the Quality Control Measures for Minoxidil API?

Quality control (QC) is paramount to ensure the safety and efficacy of Minoxidil API. QC measures include:

• Identity Testing: Confirming that the API is indeed Minoxidil, typically using spectroscopic methods like Infrared (IR) spectroscopy and Nuclear Magnetic Resonance (NMR) spectroscopy.
• Purity Assessment: Determining the percentage of Minoxidil in the sample. This is commonly done using High-Performance Liquid Chromatography (HPLC).
• Impurity Testing: Quantifying known and unknown impurities using HPLC and Gas Chromatography (GC). Limits for specific impurities are defined by pharmacopeias and regulatory guidelines.
• Assay: Measuring the exact content of Minoxidil, usually by titration or HPLC.
• Physical Characteristics: Testing for appearance, color, odor, melting point, and solubility.
• Particle Size Distribution: Relevant for formulation, this is measured using techniques like laser diffraction.
• Residual Solvents: Analyzing for the presence of residual organic solvents used during manufacturing, typically by GC.
• Water Content: Determined using Karl Fischer titration.
• Heavy Metals: Testing for the presence of heavy metals, which can be toxic.

What are the Supply Chain Risks and Mitigation Strategies for Minoxidil API?

The supply chain for Minoxidil API, like many APIs, faces several risks:

Supply Chain Risks:

• Geographic Concentration: Over-reliance on a few countries (primarily China and India) for manufacturing creates vulnerability to geopolitical events, trade disputes, natural disasters, or localized regulatory crackdowns.
• Raw Material Volatility: Fluctuations in the price and availability of key chemical precursors can impact production costs and lead times.
• Quality Control Failures: Batch failures or recalls due to quality issues can disrupt supply and damage reputation.
• Regulatory Changes: Evolving GMP requirements, environmental regulations, or stricter impurity limits can necessitate costly process modifications.
• Logistical Disruptions: Global shipping delays, port congestion, or transportation breakdowns can impede timely delivery.
• Intellectual Property Disputes: While the core Minoxidil molecule is off-patent, manufacturing processes or specific polymorphs might be subject to IP protection, potentially creating supply constraints.

Mitigation Strategies:

• Supplier Diversification: Identifying and qualifying alternative API manufacturers in different geographic regions.
• Dual Sourcing: Engaging multiple approved suppliers for critical APIs.
• Strategic Inventory Management: Maintaining sufficient safety stock of API to buffer against short-term supply disruptions.
• Robust Quality Agreements: Establishing detailed quality agreements with API suppliers that define specifications, testing methods, change control procedures, and audit rights.
• Regular Audits: Conducting frequent on-site audits of API manufacturing facilities to ensure ongoing compliance with GMP and quality standards.
• Supply Chain Transparency: Gaining visibility into the sub-tier suppliers of critical raw materials used by the API manufacturers.
• Long-Term Contracts: Negotiating longer-term supply agreements with key suppliers to secure pricing and volume commitments.
• Regulatory Intelligence: Proactively monitoring regulatory updates and trends in key manufacturing regions.
• Technology and Process Improvement: Investing in R&D to develop more efficient, greener, and robust manufacturing processes that can adapt to changing requirements.

What is the Market Outlook for Minoxidil API?

The market for Minoxidil API is driven by the increasing prevalence of androgenetic alopecia globally, particularly in aging populations and among younger demographics experiencing stress-related hair loss [6].

• Growing Demand: The expanding patient population seeking effective hair loss treatments fuels consistent demand for Minoxidil.
• Generics Market: With the patent expiry of the original Minoxidil formulations, the generic market has become dominant, leading to price competition among API manufacturers.
• Emerging Markets: Increased healthcare access and growing awareness of hair loss treatments in developing economies are expected to contribute to market growth.
• Innovation: While Minoxidil is a mature product, research into novel delivery systems or combination therapies could influence future demand dynamics.
• Regulatory Scrutiny: Continued stringent regulatory oversight by global health authorities will likely favor established manufacturers with strong compliance records.

The competitive landscape for Minoxidil API is characterized by a balance between large, established producers and smaller, agile manufacturers. Pricing is a significant factor, with Chinese and Indian manufacturers generally offering more competitive costs due to economies of scale and lower manufacturing overheads.

Key Takeaways

• Minoxidil is the sole API for MINITRAN, a topical hair loss treatment.
• The global supply is concentrated among manufacturers in China and India, with Aarti Industries and Sarthak Remedies being key Indian players and Anqiu Lexiang, Hebei Veyong, Xi'an Tiankai, and Shandong Xinhua prominent in China.
• Manufacturers must comply with stringent GMP, pharmacopeial standards, and maintain detailed DMFs.
• Quality control is critical, encompassing identity, purity, impurity profiling, and assay testing.
• Supply chain risks include geographic concentration and raw material volatility, necessitating strategies like supplier diversification and dual sourcing.
• The Minoxidil API market is robust, driven by the global prevalence of hair loss and a strong generic pharmaceutical sector.

Frequently Asked Questions

What are the primary countries of origin for Minoxidil API?

The primary countries of origin for Minoxidil API are China and India.

Which major pharmacopeias must Minoxidil API comply with?

Minoxidil API must comply with standards set by major pharmacopeias including the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP).

How can pharmaceutical companies mitigate the risk of a single-country supply dependency for Minoxidil API?

Companies can mitigate this risk through supplier diversification, dual sourcing, maintaining strategic inventory levels, and establishing robust quality agreements with manufacturers in different regions.

What is the typical purity requirement for pharmaceutical-grade Minoxidil API?

Pharmaceutical-grade Minoxidil API typically requires a purity of 98.0% to 102.0%, as specified by pharmacopeial monographs.

Are there any specific impurity limits that manufacturers must adhere to for Minoxidil API?

Yes, pharmacopeias and regulatory agencies define strict limits for known and unknown impurities, which manufacturers must rigorously control and monitor.

Citations

[1] National Institutes of Health. (n.d.). Minoxidil. U.S. National Library of Medicine. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Minoxidil [2] U.S. Food & Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/forms-and-fees/drug-master-files [3] European Medicines Agency. (n.d.). Good manufacturing practice (GMP). Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/good-manufacturing-practice-gmp [4] United States Pharmacopeia. (n.d.). USP-NF. Retrieved from https://www.usp.org/products/usp-nf [5] R. L. Johnson, D. P. McManis, & G. L. Miller. (1977). Process for the preparation of 2,4-diamino-6-piperidinopyrimidine 3-oxide. U.S. Patent 4,031,085. [6] Global Market Insights. (n.d.). Hair Loss Treatment Market Size, Share & Growth Report, 2032. Retrieved from https://www.gminsights.com/industry-analysis/hair-loss-treatment-market